AstraZeneca Reportedly Made ~$10B Takeover Approach for Rhythm Pharmaceuticals
RYTM sits 28% above its 52-week low of $74.5 on elevated volume (4.2× avg).
Summary
AstraZeneca made a roughly $10 billion offer for Rhythm Pharmaceuticals last month, at $124 per share, according to WSJ-sourced reporting carried by Dow Jones. That is a large premium to Rhythm's current market value, which sits well below the offer figure, so the stock is likely to reprice toward deal terms. The approach lands right after a busy stretch: Rhythm signed an $855 million license-out with LG Chem on Nov. 3, posted Q3 revenue of $92.1 million (up 79% year over year), and disclosed a new $750 million five-year term loan. Those moves built out the IMCIVREE franchise — recent UK, Japan and Canada approvals plus the Japan launch — which is presumably what AstraZeneca is buying. The key question now is whether this is a firm bid or an early approach; no board response or definitive agreement has been disclosed.
At the time of this announcement, RYTM was trading at $95.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.